{"drugs":["Bleph-10","Carmol Scalp Treatment","Klaron","Ocu-Sul","Ovace","S.O.S.S.","Sodium Sulamyd","Sulf-10","Sulfacetamide Sodium"],"mono":{"0":{"id":"556880-s-0","title":"Generic Names","mono":"Sulfacetamide Sodium"},"1":{"id":"556880-s-1","title":"Dosing and Indications","sub":{"0":{"id":"556880-s-1-4","title":"Adult Dosing","mono":"<ul><li><b>Acne vulgaris:<\/b> (10% lotion) apply thin film TOPICALLY to affected areas twice a day<\/li><li><b>Bacterial infection of eye, Superficial infections including conjunctivitis:<\/b> ophthalmic solution, 1-2 drops into conjunctival sac(s) of affected eye(s) every 2-3 hr initially; taper by increasing time intervals as condition responds; usual duration 7-10 days<\/li><li><b>Bacterial infection of eye, Superficial infections including conjunctivitis:<\/b> ophthalmic ointment, apply approximately one-half inch ribbon into conjunctival sacs(s) of affected eye(s) every 3-4 hr and at bedtime; taper by increasing time intervals as condition responds; usual duration 7-10 days<\/li><li><b>Bacterial infection of skin:<\/b> wash affected areas with 10% wash daily for 8 to 10 days; rinse thoroughly with plain water<\/li><li><b>Seborrhea, Including seborrheic dermatitis and seborrhea sicca:<\/b> wash affected areas with 10% wash twice daily for 8 to 10 days; rinse thoroughly with plain water<\/li><li><b>Trachoma; Adjunct:<\/b> ophthalmic solution, 2 drops into conjunctival sac(s) of effected eye(s) every 2 hr; must be accompanied by systemic sulfonamide administration<\/li><\/ul>"},"1":{"id":"556880-s-1-5","title":"Pediatric Dosing","mono":"<ul><li><b>Acne vulgaris:<\/b> (10% lotion) 12 years of age and older, apply thin film TOPICALLY to affected areas twice a day<\/li><li><b>Bacterial infection of eye, Superficial infections including conjunctivitis:<\/b> (2 months of age and older) ophthalmic solution, 1-2 drops into conjunctival sac(s) of affected eye(s) every 2-3 hr initially; taper by increasing time intervals as condition responds; usual duration 7-10 days<\/li><li><b>Bacterial infection of eye, Superficial infections including conjunctivitis:<\/b> (2 months of age and older) ophthalmic ointment, apply approximately one-half inch ribbon into conjunctival sacs(s) of affected eye(s) every 3-4 hr and at bedtime; taper by increasing time intervals as condition responds; usual duration 7-10 days<\/li><li><b>Bacterial infection of skin:<\/b> age 12 years and older, wash affected areas with 10% wash daily for 8 to 10 days; rinse thoroughly with plain water<\/li><li><b>Seborrhea, Including seborrheic dermatitis and seborrhea sicca:<\/b> age 12 years and older, wash affected areas with 10% wash twice daily for 8 to 10 days; rinse thoroughly with plain water<\/li><\/ul>"},"3":{"id":"556880-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><ul><li>Acne vulgaris<\/li><li>Bacterial infection of eye, Superficial infections including conjunctivitis<\/li><li>Bacterial infection of skin<\/li><li>Seborrhea, Including seborrheic dermatitis and seborrhea sicca<\/li><li>Trachoma; Adjunct<\/li><\/ul><b>Non-FDA Labeled Indications<\/b><br\/>Bacterial keratitis<br\/>"}}},"3":{"id":"556880-s-3","title":"Contraindications\/Warnings","sub":[{"id":"556880-s-3-9","title":"Contraindications","mono":"hypersensitivity to sulfonamide products <br\/>"},{"id":"556880-s-3-10","title":"Precautions","mono":"<ul><li>corneal wound healing, reduced, may occur (ophthalmic ointment)<\/li><li>cross-sensitivity can occur between different sulfonamides; discontinue use if suspected<\/li><li>fatalities, although very rare, have occurred due to severe reactions to sulfonamides, including Stevens-Johnson syndrome, toxic epidermal necrolysis, fulminant hepatic necrosis, agranulocytosis, aplastic anaemia, and other blood dyscrasias; discontinue at first sign of hypersensitivity, skin rash, or other serious reaction<\/li><li>hypersensitivity reactions can occur regardless of route of administration; discontinue use if suspected<\/li><li>PABA in purulent exudate; may reduce sulfonamide effectiveness<\/li><li>prolonged use; proliferation of nonsusceptible organisms, including fungi, may occur<\/li><li>sulfite allergy (eg, anaphylactic or allergic-type reactions, life-threatening or less severe asthma) may occur; contains sodium metabisulfite; increased risk in patients with asthma (lotion)<\/li><li>systemic lupus erythematosus has been reported (cream)<\/li><li>report suspected adverse reactions to the US Food and Drug Administration at 1-800-FDA-1088 or www.fda.gov\/medwatch<\/li><\/ul>"},{"id":"556880-s-3-11","title":"Pregnancy Category","mono":"Sulfacetamide: C (FDA)<br\/>"},{"id":"556880-s-3-12","title":"Breast Feeding","mono":"Sulfacetamide: Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"4":{"id":"556880-s-4","title":"Drug Interactions","sub":[{"id":"556880-s-4-13","title":"Contraindicated","mono":"<ul>Methenamine (theoretical)<\/ul>"}]},"5":{"id":"556880-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><br\/><b>Ophthalmic:<\/b>Application site irritation<br\/><b>Serious<\/b><ul><li><b>Dermatologic:<\/b>Stevens-Johnson syndrome, Toxic epidermal necrolysis<\/li><li><b>Hematologic:<\/b>Agranulocytosis, Aplastic anemia<\/li><li><b>Hepatic:<\/b>Hepatic necrosis<\/li><li><b>Immunologic:<\/b>Hypersensitivity reaction<\/li><\/ul>"},"6":{"id":"556880-s-6","title":"Drug Name Info","sub":{"0":{"id":"556880-s-6-17","title":"US Trade Names","mono":"<ul><li>Bleph-10<\/li><li>Carmol Scalp Treatment<\/li><li>Klaron<\/li><li>Ocu-Sul<\/li><li>Ovace<\/li><li>S.O.S.S.<\/li><li>Sodium Sulamyd<\/li><li>Sulf-10<\/li><\/ul>"},"2":{"id":"556880-s-6-19","title":"Class","mono":"<ul><li>Antibacterial<\/li><li>Antibiotic<\/li><li>Antiseborrheic<\/li><li>Dermatological Agent<\/li><li>Sulfonamide<\/li><\/ul>"},"3":{"id":"556880-s-6-20","title":"Regulatory Status","mono":"RX\/OTC<br\/>"},"4":{"id":"556880-s-6-21","title":"Generic Availability","mono":"Yes<br\/>"}}},"7":{"id":"556880-s-7","title":"Mechanism Of Action","mono":"Sulfacetamide sodium is an antibacterial sulfonamide with bacteriostatic activity against susceptible microorganisms. It acts as a competitive antagonist of para-aminobenzoic acid utilization which is an important component of bacterial growth. It also competitively blocks the enzyme dihydropteroate synthetase which inhibits the condensation of pteridine with aminobenzoic acid, thus resulting in prevention of synthesis of bacterial dihydrofolic acid.<br\/>"},"8":{"id":"556880-s-8","title":"Pharmacokinetics","sub":{"0":{"id":"556880-s-8-23","title":"Absorption","mono":"<ul><li>Oral: readily absorbed<\/li><li>Topical: not known<\/li><\/ul>"},"3":{"id":"556880-s-8-26","title":"Excretion","mono":"Renal: largely unchanged <br\/>"},"4":{"id":"556880-s-8-27","title":"Elimination Half Life","mono":"7 h to 13 h <br\/>"}}},"9":{"id":"556880-s-9","title":"Administration","mono":"<b>Topical<\/b><br\/><ul><li>(wash) for dermatological use only; not for ophthalmic use<\/li><li>(wash) regular shampooing following use is not required; shampoo hair at least once a week<\/li><li>(wash) avoid contact with eyes and mucous membranes<\/li><li>(lotion) apply thin film to affected areas<\/li><\/ul>"},"10":{"id":"556880-s-10","title":"Monitoring","mono":"symptomatic improvement<br\/>"},"11":{"id":"556880-s-11","title":"How Supplied","mono":"<ul><li><b>Generic<\/b><br\/><ul><li>Ophthalmic Ointment: 10 %<\/li><li>Ophthalmic Solution: 10 %<\/li><li>Topical Gel\/Jelly: 10 %<\/li><li>Topical Lotion: 10 %<\/li><li>Topical Shampoo: 10 %<\/li><li>Topical Soap: 10 %<\/li><li>Topical Suspension: 10 %<\/li><\/ul><\/li><li><b>Bleph-10<\/b><br\/>Ophthalmic Solution: 10 %<br\/><\/li><li><b>Klaron<\/b><br\/>Topical Lotion: 10 %<br\/><\/li><li><b>Mexar<\/b><br\/>Topical Soap: 10 %<br\/><\/li><li><b>Ovace Plus Creme<\/b><br\/>Topical Cream: 10 %<br\/><\/li><li><b>Ovace Plus Lotion<\/b><br\/>Topical Lotion: 9.8 %<br\/><\/li><li><b>Ovace Plus Shampoo<\/b><br\/>Topical Shampoo: 10 %<br\/><\/li><li><b>Ovace Plus Wash Clean Gel<\/b><br\/>Topical Gel\/Jelly: 10 %<br\/><\/li><li><b>Ovace Plus Wash<\/b><br\/>Topical Soap: 10 %<br\/><\/li><li><b>Ovace Wash<\/b><br\/>Topical Soap: 10 %<br\/><\/li><li><b>Seb-Prev Wash<\/b><br\/>Topical Soap: 10 %<br\/><\/li><\/ul>"},"12":{"id":"556880-s-12","title":"Toxicology","sub":[{"id":"556880-s-12-31","title":"Clinical Effects","mono":"<b>SULFONAMIDES<\/b><br\/>OVERDOSE: Data limited. Effects may be an extension of adverse events reported with sulfonamides. Methemoglbinemia has been reported after overdose. ADVERSE EVENTS: Adverse reactions to sulfonamides can involve nearly every organ system; many effects appear to be hypersensitivity reactions, and are dose related. DERMATOLOGIC: Various dermatological reactions, including rash, pruritus, erythema nodosum, and quite severe and often fatal erythema multiforme of the Stevens-Johnson type have been reported. Lyell's Syndromes are usually associated with the use of a long-acting sulfonamides. GASTROINTESTINAL: Nausea and vomiting are common. HYPERSENSITIVITY REACTION: Transient myopia, conjunctivitis, hepatic injury, and keratitis may occur in association with a hypersensitivity reaction. NEUROLOGIC: Headache, depression, and hallucinations have been reported with therapy.  <br\/>"},{"id":"556880-s-12-32","title":"Treatment","mono":"<b>SULFONAMIDES <\/b><br\/><ul><li>Decontamination: Activated charcoal.<\/li><li>Support: Treatment is symptomatic and supportive.<\/li><li>Hypersensitivity reaction: For signs and symptoms of anaphylaxis administer oxygen, establish an airway, and give epinephrine and diphenhydramine as indicated.<\/li><li>Hypotensive episode: IV isotonic fluids at 10 to 20 mL\/kg, dopamine, norepinephrine.<\/li><li>Methemoglobinemia: Obtain a methemoglobin level. Treat symptomatic methemoglobinemia (usually at methemoglobin levels above 20% to 30%) with methylene blue and oxygen therapy.<\/li><li>Seizure: Seizures have been reported infrequently. Give benzodiazepines, barbiturates as indicated.<\/li><li>Monitoring of patient:  Obtain a baseline CBC, electrolytes including glucose level and hepatic enzymes and renal function tests.<\/li><\/ul>"},{"id":"556880-s-12-33","title":"Range of Toxicity","mono":"<b>SULFONAMIDES<\/b><br\/>TOXICITY: Methemoglobinemia has been reported after ingestion of 15 g sulfamethoxazole. Many of the adverse effects related to sulfonamides are hypersensitivity reactions, that develop at therapeutic doses.  The incidence of adverse effects increases with higher doses. THERAPEUTIC DOSE: Varies by agent.<br\/>"}]},"13":{"id":"556880-s-13","title":"Clinical Teaching","mono":"<ul><li>The ophthalmic form of drug may cause burning, conjunctival hyperemia, excessive tearing, and pain in eye.<\/li><li>Topical form may cause skin irritation.<\/li><li>Advise patients on proper administration technique.<\/li><li>Patients using topical form should avoid covering treated skin with cosmetics or other skin products.<\/li><\/ul>"}}}